Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth

Journal of Immunology

Volumn 178, Issue 1, 2007, Pages 111-121

  Gururajan, Murali ^a,b   Dasu, Trivikram ^a   Shahidain, Seif ^a   Jennings, C Darrell ^a   Robertson, Darrell A ^a   Rangnekar, Vivek M ^a,b,c   Bondada, Subbarao ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; PROTEIN BAD; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE SYK; TURMERIC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTHRITIS; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; CURCUMA LONGA; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 33845927271     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.1.111     Document Type: Article

References (68)

1. Cattoretti, G., L. Pasqualucci, G. Ballon, W. Tam, S. V. Nandula, Q. Shen, T. Mo, V. V. Murty, and R. Dalla-Favera. 2005. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7: 445-455.
2. Shishodia, S., G. Sethi, and B. B. Aggarwal. 2005. Curcumin: getting back to the roots. Ann. NY Acad. Sci. 1056: 206-217.
3. Ranjan, D., T. D. Johnston, G. Wu, L. Elliott, S. Bondada, and M. Nagabhuskhan. 1998. Curcumin blocks cyclosporine A-resistant CD28 co-stimulatory pathway of human T cell proliferation. J. Surg. Res. 77: 174-178.
4. Jiang, M. C., H. F. Yang-Yen, J. J. Yen, and J. K. Lin. 1996. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr. Cancer 26: 111-120.
5. Singletary, K., C. MacDonald, M. Wallig, and C. Fisher. 1996. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett. 103: 137-141.
6. Osawa, T., and Y. Kato. 2005. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann. NY Acad. Sci. 1043: 440-451.
7. Kuroda, M., Y. Mimaki, T. Nishiyama, T. Mae, H. Kishida, M. Tsukagawa, K. Takahashi, T. Kawada, K. Nakagawa, and M. Kitahara. 2005. Hypoglycemic effects of turmeric (Curcuma longa L. Rhizomes) on genetically diabetic KK-Ay mice. Biol. Pharm. Bull. 28: 937-939.
8. Huang, M. T., Y. R. Lou, W. Ma, H. L. Newmark, K. R. Reuhl, and A. H. Conney. 1994. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 54: 5841-5847.
9. Shishodia, S., P. Potdar, C. G. Gairola, and B. B. Aggarwal. 2003. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 24: 1269-1279.
10. Bharti, A. C., S. Shishodia, J. M. Reuben, D. Weber, R. Alexanian, S. Raj-Vadhan, Z. Estrov, M. Talpaz, and B. B. Aggarwal. 2004. Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103: 3175-3184.
11. Bharti, A. C., N. Donato, and B. B. Aggarwal. 2003. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 171: 3863-3871.
12. L, NF-κB, and p53. Clin. Immunol. 93: 152-161.
13. Ranjan, D., T. D. Johnston, K. S. Reddy, G. Wu, S. Bondada, and C. Chen. 1999. Enhanced apoptosis mediates inhibition of EBV-transformed lymphoblastoid cell line proliferation by curcumin. J. Surg. Res. 87: 1-5.
14. Kumar, A. P., G. E. Garcia, R. Ghosh, R. V. Rajnarayanan, W. L. Alworth, and T. J. Slaga. 2003. 4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF κB cell survival signaling pathway: potential for prostate cancer management. Neoplasia 5: 255-266.
15. Osaki, M., M. Oshimura, and H. Ito. 2004. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676.
16. Mok, C. L., G. Gil-Gomez, O. Williams, M. Coles, S. Taga, M. Tolaini, T. Norton, D. Kioussis, and H. J. Brady. 1999. Bad can act as a key regulator of T cell apoptosis and T cell development. J. Exp. Med. 189: 575-586.
17. Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M. E. Greenberg. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
18. Monroe, J. G., V. L. Seyfert, C. S. Owen, and N. Sykes. 1989. Isolation and characterization of a B lymphocyte mutant with altered signal transduction through its antigen receptor. J. Exp. Med. 169: 1059.
19. Muthukkumar, S., C. Venkataraman, T. Woods, and S. Bondada. 1997. Activation of syk in an immature B cell line does not require lyn activity. Mol. Immunol. 34: 865-875.
20. Cornall, R. J., A. M. Cheng, T. Pawson, and C. C. Goodnow. 2000. Role of Syk in B-cell development and antigen-receptor signaling. Proc. Natl. Acad. Sci. USA 97: 1713-1718.
21. Saijo, K., C. Schmedt, I. H. Su, H. Karasuyama, C. A. Lowell, M. Reth, T. Adachi, A. Patke, A. Santana, and A. Tarakhovsky. 2003. Essential role of Src-family protein tyrosine kinases in NF-κB activation during B cell development. Nat. Immunol. 4: 274-279.
22. Gold, M. R., M. P. Scheid, L. Santos, M. Dang-Lawson, R. A. Roth, L. Matsuuchi, V. Duronio, and D. L. Krebs. 1999. The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase. J. Immunol. 163: 1894-1905.
23. Mukhopadhyay, A., C. Bueso-Ramos, D. Chatterjee, P. Pantazis, and B. B. Aggarwal. 2001. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20: 7597-7609.
24. Aggarwal, B. B., and S. Shishodia. 2004. Suppression of the nuclear factor-κB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. NY Acad. Sci. 1030: 434-441.
25. Udhayakumar, V., P. H. Brodeur, M. S. Rajagopalan, S. Zimmer, K. E. Pollok, and B. Subbarao. 1989. Isolation and immunological characterization of a group of new B lymphomas from CBA mice. Clin. Immunol. Immunopathol. 51: 240-251.
26. Gururajan, M., R. Chui, A. K. Karuppannan, J. Ke, C. D. Jennings, and S. Bondada. 2005. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106: 1382-1391.
27. Landers, C. D., and S. Bondada. 2005. CpG oligodeoxynucleotides stimulate cord blood mononuclear cells to produce immunoglobulins. Clin. Immunol. 116: 236-245.
28. Madsen, M., H. E. Johnson, P. W. Hansen, and S. E. Christiansen. 1980. Isolation of human T and B lymphocytes by E-rosette gradient centrifugation: characterization of the isolated subpopulations. J. Immunol. Methods 33: 323-336.
29. Vasudevan, K. M., S. Gurumurthy, and V. M. Rangnekar. 2004. Suppression of PTEN expression by NF-κB prevents apoptosis. Mol. Cell. Biol. 24: 1007-1021.
30. Salvesen, G. S., and V. M. Dixit. 1997. Caspases: intracellular signaling by proteolysis. Cell 91: 443-446.
31. Merino, R., D. A. M. Grillot, P. L. Simonian, S. Muthukkumar, W. C. Fanslow, S. Bondada, and G. Nunez. 1995. Modulation of anti-IgM-induced B cell apoptosis by bcl-xL and CD40: dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction. J. Immunol. 155: 3830-3838.
32. Tan, J. E.-L., S.-C. Wong, S. K.-E. Gan, S. Xu, and K.-P. Lam. 2001. The adaptor protein BLNK is required for B cell antigen receptor-induced activation of nuclear factor-κB and cell cycle entry and survival of B lymphocytes. J. Biol. Chem. 276: 20055-20063.
33. Eyster, C. A., Q. S. Duggins, and A. L. Olson. 2005. Expression of constitutively active Akt/protein kinase B signals GLUT4 translocation in the absence of an intact actin cytoskeleton. J. Biol. Chem. 280: 17978-17985.
34. Liu, X., J. Powlas, Y. Shi, A. X. Oleksijew, A. R. Shoemaker, R. De Jong, T. Oltersdorf, V. L. Giranda, and Y. Luo. 2004. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth. Anticancer Res. 24: 2697-2704.
35. Patra, A. K., S. Y. Na, and U. Bommhardt. 2004. Active protein kinase B regulates TCR responsiveness by modulating cytoplasmic-nuclear localization of NFAT and NF-κB proteins. J. Immunol. 172: 4812-4820.
36. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 307: 1098-1101.
37. Ding, J., T. Takano, S. Gao, W. Han, C. Noda, S. Yanagi, and H. Yamamura. 2000. Syk is required for the activation of Akt survival pathway in B cells exposed to oxidative stress. J. Biol. Chem. 275: 30873-30877.
38. Craxton, A., A. Jiang, T. Kurosaki, and E. A. Clark. 1999. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. J. Biol. Chem. 274: 30644-30650.
39. Yamazaki, T., K. Takeda, K. Gotoh, H. Takeshima, S. Akira, and T. Kurosaki. 2002. Essential immunoregulatory role for BCAP in B cell development and function. J. Exp. Med. 195: 535-545.
40. Carver, D. J., M. J. Aman, and K. S. Ravichandran. 2000. SHIP inhibits Akt activation in B cells through regulation of Akt membrane localization. Blood 96: 1449-1456.
41. Hutchcroft, J. E., M. L. Harrsion, and R. L. Geahlen. 1991. B lymphocyte activation is accompanied by phosphorylation of a 72-kDa protein-tyrosine kinase. J. Biol. Chem. 266: 14846-14849.
42. Maloney, D. G. 1999. Preclinical and phase I and II trials of rituximab. Semin. Oncol. 26: 74-78.
43. Maloney, D. G., A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T. M. Liles, B. K. Dallaire, et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
44. Ruby, A. J., G. Kuttan, K. D. Babu, K. N. Rajasekharan, and R. Kuttan. 1995. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 94: 79-83.
45. Downward, J. 2004. PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 15: 177-182.
46. Romashkova, J. A., and S. S. Makarov. 1999. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90.
47. Ozes, O. N., L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer, and D. B. Donner. 1999. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85.
48. Aggarwal, S., H. Ichikawa, Y. Takada, S. K. Sandur, S. Shishodia, and B. B. Aggarwal. 2006. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation. Mol. Pharmacol. 69: 195-206.
49. Turner, M., E. Schweighoffer, F. Colucci, J. P. Di Santo, and V. L. Tybulewicz. 2000. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol. Today 21: 148-154.
50. Turner, M., A. Gulbranson-Judge, M. E. Quinn, A. E. Walters, I. C. MacLennan, and V. L. Tybulewicz. 1997. Syk tyrosine kinase is required for the positive selection of immature B cells into the recirculating B cell pool. J. Exp. Med. 186: 2013-2021.
51. Turner, M., P. J. Mee, P. S. Costello, O. Williams, A. A. Price, L. P. Duddy, M. T. Furlong, R. L. Geahlen, and V. L. Tybulewicz. 1995. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 378: 298-302.
52. Moon, K. D., C. B. Post, D. L. Durden, Q. Zhou, P. De, M. L. Harrison, and R. L. Geahlen. 2005. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J. Biol. Chem. 280: 1543-1551.
53. Hong, J. J., T. M. Yankee, M. L. Harrison, and R. L. Geahlen. 2002. Regulation of signaling in B cells through the phosphorylation of Syk on linker region tyrosines: a mechanism for negative signaling by the Lyn tyrosine kinase. J. Biol. Chem. 277: 31703-31714.
54. Singh, S., and B. B. Aggarwal. 1995. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). [Published erratum appears in 1995 J. Biol. Chem. 270: 30235.]
55. J. Biol. Chem. 270: 24995-25000.
56. Takano, T., K. Sada, and H. Yamamura. 2002. Role of protein-tyrosine kinase syk in oxidative stress signaling in B cells. Antioxid. Redox Signal. 4: 533-541.
57. Pogue, S. L., T. Kurosaki, J. Bolen, and R. Herbst. 2000. B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase. J. Immunol. 165: 1300-1306.
58. Takada, Y., and B. B. Aggarwal. 2004. TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-κB activation, and apoptosis. J. Immunol. 173: 1066-1077.
59. 2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-kinase and Syk-mediated pathways. J. Biol. Chem. 279: 10883-10891.
60. Kim, H. Y., E. J. Park, E. H. Joe, and I. Jou. 2003. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J. Immunol. 171: 6072-6079.
61. Leu, T. H., S. L. Su, Y. C. Chuang, and M. C. Maa. 2003. Direct inhibitory effect of curcumin on Src and focal adhesion kinase activity. Biochem. Pharmacol. 66: 2323-2331.
62. Wang, L., E. Devarajan, J. He, S. P. Reddy, and J. L. Dai. 2005. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res. 65: 10289-10297.
63. Gatalica, Z., and Z. Bing. 2005. Syk tyrosine kinase expression during multistep mammary carcinogenesis. Croat. Med. J. 46: 372-376.
64. Toyama, T., H. Iwase, H. Yamashita, Y. Hara, Y. Omoto, H. Sugiura, Z. Zhang, and Y. Fujii. 2003. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett. 189: 97-102.
65. Yuan, Y., R. Mendez, A. Sahin, and J. L. Dai. 2001. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 61: 5558-5561.
66. Tohyama, Y., T. Takano, and H. Yamamura. 2004. B cell responses to oxidative stress. Curr. Pharm. Des. 10: 835-839.
67. Kraus, M., M. B. Alimzhanov, N. Rajewsky, and K. Rajewsky. 2004. Survival of resting mature B lymphocytes depends on BCR signaling via the Igα/β heterodimer. Cell 117: 787.
68. Gururajan, M., C. D. Jennings, and S. Bondada. 2006. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J. Immunol. 176: 5715-5719.